Fig. 1

Cell-type-specific inhibition of JAK1 could improve therapeutic efficacy in allergic lung inflammation. (left side) Systemic inhibition of JAK1 reduced inflammatory responses in lymphocytes but is compensated by reduced anti-inflammatory actions of vagal sensory nerves in context of allergic lung inflammation. (right side) Lymphocyte-restricted JAK1 inhibition through targeted delivery of JAK1 inhibitors via antibodies, aptamers or other molecules could overcome this limitation. Selective inhibition of JAK1 in lymphocytes could inhibit the pro-inflammatory actions in these cells while retaining the anti-inflammatory actions through CGRPβ in vagal sensory nerves. Created with Biorender.com